For the roughly 6 million Americans living with atrial fibrillation, catheter ablation has become an increasingly common treatment, but the procedure still typically keeps patients sedated on a table for well over an hour. A new catheter system from Field Medical is designed to change that math. In early clinical testing, the company’s FieldForce ablation system completed the core step of the procedure, isolating the pulmonary veins, in a median time of 12.5 minutes, creating each lesion in under 200 milliseconds.
Field Medical presented those results from its first-in-human Field PULSE trial at the AF Symposium 2026 in late April. The data are preliminary and have not been peer-reviewed, but they arrive at a moment when multiple companies are racing to prove that pulsed-field ablation, or PFA, can outperform the heat- and cold-based methods that have dominated the field for decades.
What the early data show
The Field PULSE trial is a prospective, single-arm feasibility study designed to test what the company calls a high-voltage, sub-second pulsed-field waveform. According to Field Medical’s announcement, operators used the FieldForce catheter to achieve pulmonary vein isolation, the standard procedural goal in AF ablation, in a median of 12.5 minutes. Each energy application created a lesion in less than 200 milliseconds.
Those numbers stand out against current benchmarks. Conventional thermal ablation, whether using radiofrequency heat or cryoballoon freezing, typically requires 60 minutes or more for the isolation step, according to published procedural data. If the FieldForce speed holds up in larger studies, it could meaningfully reduce the time patients spend under sedation, lower procedural risk, and allow hospitals to treat more patients per day, a practical concern as demand for AF ablation continues to grow.
Pulmonary vein isolation works by intentionally scarring the electrically active tissue where the pulmonary veins meet the left atrium. That scar tissue blocks the erratic electrical signals responsible for the chaotic heart rhythm that defines atrial fibrillation. The technique is the same regardless of energy source; what differs is how quickly and precisely each system delivers it.
A crowded development pipeline
Field Medical is not alone. Pulse Biosciences is running a separate first-in-human feasibility study for its CellFX Nano-PFA 360 catheter, registered on ClinicalTrials.gov under identifier NCT06696170. According to that registry listing, the trial is a prospective, single-arm study evaluating initial safety and performance in AF patients. The record lists the study status as recruiting, with sites located outside the United States. The parallel development of competing devices reflects broad industry confidence that PFA represents a commercially viable next step, not just a laboratory concept.
Both programs build on the clinical foundation laid by the ADVENT trial, a randomized study published in the New England Journal of Medicine that compared pulsed-field ablation (using the Farapulse system, now owned by Boston Scientific) with conventional thermal ablation for paroxysmal atrial fibrillation. The ADVENT results, indexed on PubMed, showed that PFA matched thermal methods in both safety and effectiveness. That finding gave the broader device industry a green light to develop next-generation PFA systems with faster waveforms, different electrode configurations, and integrated cardiac mapping.
What remains uncertain
Speed is an appealing metric, but it is not the only one that matters. The Field PULSE data presented at the symposium came from a company press release, not a peer-reviewed manuscript. No detailed accounting of adverse events, patient demographics, operator variability, or lesion durability has been published in the medical literature as of May 2026. The 12.5-minute median and sub-200-millisecond lesion times describe acute procedural performance. Whether those fast lesions remain intact at six or twelve months, the standard windows for assessing arrhythmia recurrence, is unknown.
The same limitations apply to the Pulse Biosciences program. As a single-arm feasibility trial, it lacks a comparator group and is built to assess basic safety and device performance, not to prove superiority over existing tools. Publicly available records do not yet detail final enrollment numbers, long-term follow-up plans, or independently adjudicated safety outcomes.
Crucially, no head-to-head comparisons exist between these newer systems and the Farapulse technology validated in ADVENT. Each catheter uses different waveform parameters and energy delivery profiles. Whether one approach proves safer or more durable than another will require years of comparative data and, ideally, randomized trials that test competing PFA platforms against each other or against the best thermal tools available.
Neither the FieldForce system nor the CellFX Nano-PFA 360 has received FDA clearance or approval for commercial use. Both remain investigational. The path from feasibility data to a cleared product typically involves larger pivotal studies, manufacturing inspections, and sometimes advisory panel review. Patients interested in these specific devices can access them only through clinical trial enrollment at designated sites, with strict eligibility criteria and structured follow-up schedules.
What this means for patients and clinicians
The strongest evidence in this space still belongs to the ADVENT trial, which used a randomized design, enrolled a substantial patient population, and survived peer review. First-in-human feasibility studies like Field PULSE and the CellFX program sit at an earlier rung on the evidence ladder. They are designed to show that a device can be used safely in a small, closely monitored group. They are not powered to detect uncommon complications or to provide definitive comparisons with existing therapies. Positive feasibility results are a signal to proceed to larger trials, not a reason to change clinical practice.
Company press releases highlight metrics chosen to present a technology favorably. That does not make the numbers inaccurate, but it does mean they have not undergone the independent scrutiny that peer review and regulatory evaluation provide. The 12.5-minute isolation time and sub-200-millisecond lesion speed should be understood as preliminary performance signals, not settled benchmarks.
For patients weighing their options, the distinction between experimental and standard care is important. Enrolling in a feasibility trial can offer access to new technology and close medical follow-up, but it also carries uncertainties about long-term outcomes and rare complications. Anyone considering participation should discuss the investigational nature of the device, available alternatives, and the specific follow-up requirements with their electrophysiologist.
Why the next round of trials will matter most
PFA as a technique has cleared its first major clinical hurdle: the ADVENT trial proved it can match thermal ablation in a rigorous, randomized setting. The question now is whether next-generation systems like FieldForce and CellFX can translate dramatic speed gains into better patient outcomes, fewer complications, or broader access to AF treatment. Answering that will take larger trials, longer follow-up, and transparent reporting of both successes and setbacks. The early numbers are striking. The hard work of proving they matter is just beginning.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
